Scientific publications

Phase II Trial of Radiation Dose Escalation with Conformal External Beam Radiotherapy and high-Dose-Rate Brachytherapy Combined with long-Term Androgen Suppression in Unfavorable Prostate Cancer: Feasibility Report

Jeanette Valero M.D. (1), Mauricio Cambeiro M.D. [SP] (1), Carlos Galán M.D. (2), Mercedes Teijeira M.D. (4), Pilar Romero M.D. (5), Marta Moreno M.D. [SP] (1), Raquel Ciérvide M.D. (1), José Javier Aristu M.D. [SP](1) and Rafael Martínez-Monge M.D. (1)
(1) Department of Oncology, Clínica Universitaria de Navarra, University of Navarre, Navarre, Spain
(2) Department of Radiation Oncology, Hospital de la Rioja, Logroño, Spain
(3) Department of Urology, Clínica Universitaria de Navarra, University of Navarre, Navarre, Spain
(4) Department of Radiation Oncology, Hospital Divino Vallés, Burgos, Spain
(5)Department of Radiation Oncology, Hospital de Navarra, Pamplona, Spain

Magazine: International Journal of Radiation Oncology, Biology, Physics

Date: May 8, 2009

Urology [SP] Radiation Oncology

To determine the feasibility of combined long-term luteinizing hormone-releasing hormone agonist-based androgen suppressive therapy (AST) and dose escalation with high-dose-rate (HDR) brachytherapy for high-risk (HRPC) or very-high-risk prostate cancer (VHRPC).

Between January 2001 and October 2006, 134 patients (median age, 70 years) with either National Comprehensive Cancer Network criteria-defined HRPC (n = 47, 35.1%) or VHRPC (n = 87, 64.9%) were prospectively enrolled in this Phase II trial. Tumor characteristics included a median pretreatment prostate-specific antigen level of 14.6 ng/mL, a median clinical stage of T2c, and a median Gleason score of 7. Three-dimensional conformal radiotherapy (54 Gy in 30 fractions) was followed by HDR brachytherapy (19 Gy in 4 b.i.d. treatments). Androgen suppressive therapy started 0-3 months before three-dimensional conformal radiotherapy and continued for 2 years.

One implant was repositioned with a new procedure (0.7%). Five patients (3.7%) discontinued AST at a median of 13 months (range, 6-18 months) because of disease progression (n = 1), hot flashes (n = 2), fatigue (n = 1), and impotence (n = 1). After a median follow-up of 37.4 months (range, 24-90 months), the highest Radiation Therapy Oncology Group-defined late urinary toxicities were Grade 0 in 47.8%, Grade 1 in 38.1%, Grade 2 in 7.5%, and Grade 3 in 6.7% of patients. Maximal late gastrointestinal toxicities were Grade 0 in 73.1%, Grade 1 in 16.4%, Grade 2 in 7.5%, and Grade 3 in 2.9% of patients. There were no Grade 4 or 5 events.

Intermediate-term results show that dose escalation with HDR brachytherapy combined with long-term AST is feasible and has a toxicity profile similar to that reported by previous HDR brachytherapy studies.

CITATION  Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):386-92

you maybe interested


The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra


Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra